Skip to main content
SpringerLink
Log in

As-required administration of sodium glucose co-transporter-2 inhibitors: three case studies

  • Commentary
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Sodium glucose co-transporter-2 (SGLT2) inhibitors are used to reduce glycated hemoglobin (HbA1c) levels. Although they have the potential to reduce body weight in patients with type 2 diabetes mellitus (T2DM), some patients may gain weight. We found that the effects of the SGLT2 inhibitor ipragliflozin were maintained for 48 h when used in combination with nifedipine, so we considered that a daily SGLT2 inhibitor might be unnecessary. Therefore, we investigated whether as-required single doses of an SGLT2 inhibitor would be clinically relevant in three patients having difficulty maintaining blood glucose control when they were unable to exercise or during social situations. All three patients demonstrated improved HbA1c levels with as-required single doses of an SGLT2 inhibitor. These patients experienced no adverse effects or weight gain relative to taking an SGLT2 inhibitor daily. Thus, as-required single-dose SGLT2 inhibitors could be one of the many options to improve blood glucose control in T2DM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Vivian EM. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Am J Health Syst Pharm. 2015;72(5):361–72.

    Article  CAS  PubMed  Google Scholar 

  2. Hamamoto H, Noda M. Body weight gain and hyperphagia after administration of SGLT-2 inhibitor: a case report. Am J Case Rep. 2015;2015(16):863–7.

    Article  Google Scholar 

  3. Okada S, Shibusawa R, Tagaya Y, et al. Glycosuria mediated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report. J Med Case Rep. 2014;8:428. https://doi.org/10.1186/1752-1947-8-428.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Osaki A, Okada S, Saito T, et al. Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy. J Diabetes Investig. 2016;7(5):751–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Yamada E, Saito T, Niijima Y, et al. Sodium glucose co-transporter 2 inhibitors successfully attenuated seasonal change of glycated haemoglobin A1c. Clin Med (Lond). 2017;17(4):377–8.

    Article  PubMed  Google Scholar 

  6. Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). 2017;8:6. https://doi.org/10.3389/fendo.2017.00006.

    PubMed  PubMed Central  Google Scholar 

  7. Kohler S, Zeller C, Iliev H, et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I–III clinical trials. Adv Ther. 2017;34(7):1707–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Dr. Jeffrey E Pessin (Albert Einstein College of Medicine, Bronx, NY, USA) for critical suggestions on our manuscript.

Funding

No funding was received for this report.

Author information

Authors and Affiliations

  1. Division of Endocrinology and Diabetes Mellitus, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan

    Yoko Shimoda, Eijiro Yamada, Tsugumichi Saito, Junichi Okada, Shuichi Okada & Masanobu Yamada

  2. Kan-etsu Hospital, 71 Kitahara-machi, Takasaki, Gunma, 370-3513, Japan

    Tsugumichi Saito, Yawara Niijima, Junichi Okada & Shuichi Okada

Authors
  1. Yoko Shimoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eijiro Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tsugumichi Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yawara Niijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junichi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuichi Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masanobu Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YS, YN, and SO provided patient care. YS, EY, TS, YN, JO, SO, and MY participated in the discussion and prepared the manuscript.

Corresponding author

Correspondence to Shuichi Okada.

Ethics declarations

Ethics approval and consent to participate

Written informed consent was obtained from the patients for the publication of this manuscript and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Consent to publish

All authors understand that the information will be published without patients’ names, but that full anonymity cannot be guaranteed. We understand that the text will be available on the internet and in print and may be seen by the general public, translated into other languages, or used for commercial purposes.

Conflict of interest

The authors have no significant competing financial, professional, or personal interests that might have influenced the performance or presentation of the work described in this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shimoda, Y., Yamada, E., Saito, T. et al. As-required administration of sodium glucose co-transporter-2 inhibitors: three case studies. Drugs Ther Perspect 34, 231–233 (2018). https://doi.org/10.1007/s40267-018-0485-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0485-3

Search

Navigation